05033cam a2200553 i 45000010008000000030006000080050017000140060019000310070015000500080041000650200034001060200031001400200042001710200039002130350017002520390012002690400042002810500010003230600011003330820018003440900025003622450107003872500020004942640051005142640011005653000052005763360026006283370026006543380036006805000164007165040041008805052760009215060060036815880116037415960007038576500012038646500018038766500021038946500030039156500044039456500019039896500022040087000038040307300072040688560136041409490015042769260105042917580083043966799460OCoLC20150123042923.9m     o  d        cr |||||||||||141215t20152015paua    ob    000 0 eng d  a9780323324991qelectronic bk.  a0323324991qelectronic bk.  z9780323287869qhardcover : alk. paper  z0323287867qhardcover : alk. paper  aocn898150893  aexclude  aMMUbengerdacMMUdOCLCOdOPELSdAEU 4aQP751 4aQY 46504a616.3/997223  aInternet AccessbAEU00aClinical lipidology :ba companion to Braunwald's heart disease /c[edited by] Christie M. Ballantyne.  aSecond edition. 1aPhiladelphia, PA :bElsevier Saunders,c[2015] 4cÂ©2015  a1 online resource :billustrations (some color)  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  aComplemented by: Braunwald's heart disease / edited by Douglas L. Mann, Douglas P. Zipes, Peter Libby, Robert O. Bonow, Eugene Braunwald. 10th edition. [2015].  aIncludes bibliographical references.0 aHuman plasma lipoprotein metabolism -- Regulation and clearance of apolipoprotein B-containing lipoproteins -- Absorption and excretion of intestinal cholesterol and other sterols -- High-density lipoprotein metabolism -- Lipoproteins : mechanisms for atherogenesis and progression of atherothrombotic disease -- Impact of rare and common genetic variants on lipoprotein metabolism -- Lipoprotein oxidation : mechanisms and biotheranostic applications -- Cholesterol : concentration, ratio, and particle number -- High-density lipoprotein cholesterol and triglycerides in coronary heart disease risk assessment -- Lipoprotein(a) -- Clinical evaluation for genetic and secondary causes of dyslipidemia -- Use of high-sensitivity c-reactive protein for risk assessment -- Role of lipoprotein-associated phospholipase A2 in vascular disease -- Emerging assays -- Imaging atherosclerosis for risk stratification by cardiac computed tomography or carotid ultrasound -- Overview of general approach to management of elevated low-density lipoprotein cholesterol and mixed dyslipidemia, high triglycerides, and low high-density lipoprotein cholesterol -- Treatment guidelines overview -- Dietary patterns for the prevention and treatment of cardiovascular disease -- Exercise and lipids -- Weight loss -- Statins -- Bile acid sequestrants -- Cholesterol absorption inhibitors -- Niacin (nicotinic acid) -- Fibrates -- Omega-3 fatty acids -- Combination therapy for dyslipidemia -- Nutraceuticals and functional foods for cholesterol reduction -- Evolving targets of therapy : cholesteryl ester transfer protein inhibition -- Evolving targets of therapy : proprotein convertase subtilisin/kexin 9 inhibition -- Evolving targets of therapy : inflammation as a method to predict and prevent cardiovascular events -- Invasive imaging modalities and atherosclerosis : intravascular ultrasound -- Noninvasive imaging modalities and atherosclerosis : the role of ultrasound -- Noninvasive imaging modalities and atherosclerosis : the role of magnetic resonance imaging and positron emission tomography imaging -- Special patient populations : diabetes and metabolic syndrome -- Special patient populations : women and elderly -- Special patient populations : children and adolescents -- Special patient populations : familial hypercholesterolemia and other severe hypercholesterolemias -- Special patient populations : acute coronary syndromes -- Special patient populations : transplant recipients -- Special patient populations : chronic kidney disease -- Special patient populations : lipid abnormalities in high-risk ethnic groups -- Special patient populations : human immunodeficiency virus patients -- Therapeutic targeting of high-density lipoprotein metabolism.  aAccess restricted to authorized users and institutions.  aDescription based on online resource; title from digital title page (ClinicalKey, viewed on December 15, 2014).  a44 0aLipids. 0aLipoproteins. 0aHeartxDiseases.12aLipoproteinsxmetabolism.22aCardiovascular Diseasesxcomplications.22aDyslipidemias.22aLipid Metabolism.1 aBallantyne, Christie M.,eeditor.0 iComplemented by (expression):aBraunwald's heart disease.s10th ed.403University of Alberta Accessuhttps://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20120021461z(Unlimited Concurrent Users)  hUAINzCKEY  aInternet AccesswLCc1i6799460-1001lINTERNETmUAINTERNETrYsYtE-RESOURCEu2/5/2015xE-BOOKzCKEY01ahttp://id.loc.gov/authorities/names/n2008183970bhttp://viaf.org/viaf/21625479